[PEGS 2022] Implementing MOA-Reflective ADCC Assays using Ready-to-Use KILR Target and Effector Cells from Screening to Lot Release
- File Name/Number:
The clinical success of an ever-increasing array of biologics has led to the development of a wide spectrum of immunomodulatory agents with distinct mechanisms-of-action (MOA) targeting novel antigens. During development of antibody-based biologics, evaluation of antibody (Fc) effector functions is required by regulators as is needed for antibody dependent cell-mediated cytotoxicity (ADCC). Increasingly regulators are requiring that ADCC assays, especially those used for lot release applications, measure immune cell-mediated killing rather than a surrogate endpoint for antibody engagement of antigen on target cells.